Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Edgewise Therapeutics stock

Learn how to easily invest in Edgewise Therapeutics stock.

Edgewise Therapeutics Inc is a biotechnology business based in the US. Edgewise Therapeutics shares (EWTX) are listed on the NASDAQ and all prices are listed in US Dollars. Edgewise Therapeutics employs 42 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Edgewise Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EWTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Edgewise Therapeutics stock price (NASDAQ: EWTX)

Use our graph to track the performance of EWTX stocks over time.

Edgewise Therapeutics shares at a glance

Information last updated 2022-09-24.
Latest market close$9.60
52-week range$5.41 - $22.98
50-day moving average $10.25
200-day moving average $10.75
Wall St. target price$24.25
PE ratio 3.1592
Dividend yield $0 (0%)
Earnings per share (TTM) $2.89

Buy Edgewise Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Edgewise Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Edgewise Therapeutics price performance over time

Historical closes compared with the close of $9.6 from 2022-09-29

1 week (2022-09-22) 4.35%
1 month (2022-08-30) -3.81%
3 months (2022-06-30) 20.60%
6 months (2022-03-30) 3.67%
1 year (2021-09-30) -42.17%
2 years (2020-09-26) N/A
3 years (2019-09-26) N/A
5 years (2017-09-26) N/A

Is Edgewise Therapeutics stock undervalued or overvalued?

Valuing Edgewise Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edgewise Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Edgewise Therapeutics's P/E ratio

Edgewise Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Edgewise Therapeutics shares trade at around 3x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Edgewise Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

Edgewise Therapeutics financials

Gross profit TTM $0
Return on assets TTM -12.75%
Return on equity TTM -20.76%
Profit margin 0%
Book value $4.95
Market capitalisation $576.8 million

TTM: trailing 12 months

Edgewise Therapeutics share dividends

We're not expecting Edgewise Therapeutics to pay a dividend over the next 12 months.

Edgewise Therapeutics overview

Edgewise Therapeutics, Inc. , a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. .

Frequently asked questions

What percentage of Edgewise Therapeutics is owned by insiders or institutions?
Currently 0.907% of Edgewise Therapeutics shares are held by insiders and 88.583% by institutions.
How many people work for Edgewise Therapeutics?
Latest data suggests 42 work at Edgewise Therapeutics.
When does the fiscal year end for Edgewise Therapeutics?
Edgewise Therapeutics's fiscal year ends in December.
Where is Edgewise Therapeutics based?
Edgewise Therapeutics's address is: 3415 Colorado Avenue, Boulder, CO, United States, 80303
What is Edgewise Therapeutics's ISIN number?
Edgewise Therapeutics's international securities identification number is: US28036F1057

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site